218 related articles for article (PubMed ID: 18062730)
1. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
Tencer T; Friedman HS; Li-McLeod J; Johnson K
J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
[TBL] [Abstract][Full Text] [Related]
2. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
Margolis J; Barron JJ; Grochulski WD
J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
4. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
5. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
8. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
9. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
10. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
[TBL] [Abstract][Full Text] [Related]
11. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
12. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
13. Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
Croteau SE; Cook K; Sheikh L; Chawla A; Sammon J; Solari P; Kim B; Hinds D; Thornburg CD
J Manag Care Spec Pharm; 2021 Mar; 27(3):316-326. PubMed ID: 33645244
[No Abstract] [Full Text] [Related]
14. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
15. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of atopic manifestations in patients with atopic dermatitis--analysis of administrative claims.
Suh DC; Sung J; Gause D; Raut M; Huang J; Choi IS
J Manag Care Pharm; 2007; 13(9):778-89. PubMed ID: 18062729
[TBL] [Abstract][Full Text] [Related]
18. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
19. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
Hirsch JD; Rosenquist A; Best BM; Miller TA; Gilmer TP
J Manag Care Pharm; 2009; 15(1):32-41. PubMed ID: 19125548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
